EUVIMEDEUVIMED entdecken
Crossref

Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma

Sei Morinaga, Qinghong Han, Kohei Mizuta, Byung Mo Kang, Motokazu Sato, Michael Bouvet, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Shinji Miwa, Kentaro Igarashi, Takashi Higuchi und 3 weitere

Anticancer Research · 2024

DOI: 10.21873/anticanres.17202 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Sei Morinaga und 14 weiteren Autor:innen. Beteiligte Einrichtung: AntiCancer Inc., San Diego, CA, U.S.A. Hauptthemen laut MEDLINE: Ketones, Furans, Carbon-Sulfur Lyases, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetonesFuransCarbon-Sulfur LyasesDrug Resistance, NeoplasmFibrosarcomaHumansCell Line, TumorRecombinant ProteinsAntineoplastic AgentsDrug SynergismSarcomaPolyether Polyketides

Stichwörter der Autor:innen

Hoffman effectMethioninaseefficacyeribulineribulin-resistancefibrosarcomamethionine addictionmethionine restrictionsynergy

Substanzen

eribulinKetonesFuransCarbon-Sulfur LyasesL-methionine gamma-lyaseRecombinant ProteinsAntineoplastic AgentsPolyether Polyketides

Autor:innen und Institutionen

  • AntiCancer Inc., San Diego, CA, U.S.A.
  • Department of Surgery, University of California, San Diego, CA, U.S.A.
  • Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan.
  • AntiCancer Inc., San Diego, CA, U.S.A.; all@anticancer.com.

Zitieren

APA

Morinaga, S., Han, Q., Mizuta, K., Kang, B. M., Sato, M., Bouvet, M., Yamamoto, N., Hayashi, K., Kimura, H., Miwa, S., Igarashi, K., Higuchi, T., Tsuchiya, H., Demura, S., & Hoffman, R. M. (2024). Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma. Anticancer Research. https://doi.org/10.21873/anticanres.17202

Vancouver

Morinaga S, Han Q, Mizuta K, Kang BM, Sato M, Bouvet M, et al. Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma. Anticancer Research. 2024. doi:10.21873/anticanres.17202

BibTeX
@article{Morinaga2024,
  author = {Morinaga, Sei and Han, Qinghong and Mizuta, Kohei and Kang, Byung Mo and Sato, Motokazu and Bouvet, Michael and Yamamoto, Norio and Hayashi, Katsuhiro and Kimura, Hiroaki and Miwa, Shinji and Igarashi, Kentaro and Higuchi, Takashi and Tsuchiya, Hiroyuki and Demura, Satoru and Hoffman, Robert M},
  title = {Recombinant Methioninase Increases Eribulin Efficacy 16-fold in Highly Eribulin-resistant HT1080 Fibrosarcoma Cells, Demonstrating Potential to Overcome the Clinical Challenge of Drug-resistant Soft-tissue Sarcoma},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.17202}
}
Kostenlos starten →